Browsing Tag

VCN01

Theriva Biologics anuncia la designación de fármaco huérfano concedida por la FDA…

Eli Pacheco Jun 29, 2023 0

ROCKVILLE, Maryland, June 28, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), («Theriva» o la «Empresa»), una empresa de fase clínica que desarrolla terapias diseñadas…

Health

Theriva Biologics Announces Orphan Drug Designation Granted by the U.S. FDA for…

Eli Pacheco Jun 28, 2023 0

ROCKVILLE, Md., June 27, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat…

Health

Theriva Biologics Announces Presentation at the 14th International Oncolytic…

Eli Pacheco Oct 24, 2022 0

ROCKVILLE, Md., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics…

Health

Synthetic Biologics Announces Journal for ImmunoTherapy of Cancer Publication of…

Eli Pacheco Mar 29, 2022 0

-Data support VCN-01 acceptable safety profile with encouraging biological and clinical activity, and identify recommended Phase 2 dose (RP2D)- -Publication further supports the…